weight-loss and diet control industry

Page 4 of 10

Lars Fruergaard Jorgensen
Health

Wegovy is finally more widely available—and it’s bad news for Novo Nordisk’s profits

By
August 7, 2024
Thomas Schinecker, chief executive officer of Roche
Finance

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

By
July 29, 2024
Obesity medicine physician Dr. Nisha Patel breaks down five weight loss myths that “need to die” with Coins2Day.
Health

The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor

By
July 18, 2024
Danone and Nestle search for a way around Ozempic Revolution with high protein yogurt and vitamins against hair-loss
Health

Danone and Nestle search for a way around Ozempic Revolution with high protein yogurt and vitamins against hair-loss

By Dasha Afanasieva, Deena Shanker and Bloomberg
June 24, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, gestures while speaking during a Bloomberg Television interview in London, U.K.
Retail

Ozempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled in front of Bernie Sanders to explain why

By
June 17, 2024
Higher amounts of the low-calorie sweetener xylitol, often marketed as a healthy sugar substitute, is linked to an increased risk of cardiovascular events such as stroke and heart attack, according to a new Cleveland Clinic study.
Health

Sugar substitute xylitol may increase your risk of heart attack and stroke, new study shows. What to know about the low-calorie sweetener

By
June 14, 2024
CEO Sima Sistani didn’t think running WeightWatchers would be this hard
Newsletters

CEO Sima Sistani didn’t think running WeightWatchers would be this hard

By Emma Hinchliffe and Joey Abrams
June 11, 2024
Dr. Razia Hashmi, vice president of clinical affairs, Blue Cross Blue Shield Association, speaks during Coins2Day’s Brainstorm Health conference in Dana Point, Calif., on Tuesday, May 21, 2024.
Health

GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study

By
May 22, 2024
Nestle CEO Mark Schneider
Retail

Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs

By
May 21, 2024
Dr. Patrick Carroll (right), Hims & Hers chief medical officer, speaks during Coins2Day’s Brainstorm Health conference in Dana Point, Calif., Monday, May 20, 2024.
Conferences

Hims & Hers’ surprise 85% Wegovy discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says

By
May 21, 2024
woman shows off old oversized jeans
Health

Hims will follow its Viagra playbook and offer weight-loss drugs that are 85% cheaper than Wegovy—with Mounjaro and Zepbound in its sights next

By Madison Muller, Jessica Nix and Bloomberg
May 20, 2024
woman measures her waist
Health

Weaning off Ozempic slowly instead of quitting abruptly can help prevent patients from regaining weight, study says

By Ashleigh Furlong and Bloomberg
May 12, 2024
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk
Retail

Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition

By Naomi Kresge and Bloomberg
May 2, 2024
New York outlaws sales of diet pills and muscle-mass builders to children
Retail

New York outlaws sales of diet pills and muscle-mass builders to children

By Maysoon Khan and The Associated Press
April 26, 2024
Lars Fruergaard Jorgensen
Health

No evidence Ozempic and Wegovy raise risk of self harm, EU regulators said

By Jonel Aleccia and The Associated Press
April 13, 2024

Most Popular